Figures & data
Figure 1 Number needed to treat to prevent one incidence of MACE at 5 years by treatment with rosuvastatin relative to treatment with atorvastatin, according to risk group.
Notes: Smaller values indicate greater benefit. For the FRS 5%–10% group, no analysis was performed comparing rosuvastatin 20 mg with atorvastatin 80 mg. Adapted from Schuetz CA, van Herick A, Alperin P, Peskin B, Hsia J, Gandhi S. Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model. J Med Econ. 2012;15(6):1118–1129.Citation42 Copyright © 2015. Adapted with permission of the author and publisher (Taylor and Francis Ltd, http://www.tandfonline.com).
Abbreviations: FRS, Framingham Risk Score; MACE, major adverse cardiovascular event; SCORE, Systematic Coronary Risk Evaluation.
Abbreviations: FRS, Framingham Risk Score; MACE, major adverse cardiovascular event; SCORE, Systematic Coronary Risk Evaluation.
Figure 2 Five-year relative risk of MACE for initial treatment with rosuvastatin relative to atorvastatin, separated according to risk group.
Note: Adapted from van Herick A, Schuetz CA, Alperin P, Bullano MF, Balu S, Gandhi S. The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes model. Clinicoecon Outcomes Res. 2012;4:337–347.Citation44 Copyright © 2012; permission conveyed through Copyright Clearance Center, Inc.
Abbreviations: ATP, adult treatment panel; CI, confidence interval; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event.
Abbreviations: ATP, adult treatment panel; CI, confidence interval; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event.
Figure 3 Kaplan–Meier cumulative incidence of MACE for patients who switch from rosuvastatin to atorvastatin (dotted line) and for patients who remain on rosuvastatin (solid line).
Note: Adapted from Folse H, Sternhufvud C, Andy Schuetz C, Rengarajan B, Gandhi S. Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events. Clin Ther. 2014;36(1):58–69.Citation45
Abbreviation: MACE, major adverse cardiovascular event.
Abbreviation: MACE, major adverse cardiovascular event.
